Bristol-Myers Squibb | BMY - Ebitda



Bristol-Myers Squibb reported $3.27B in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
AbbVie USD 4.4B 2.52B Mar/2025
Abbott USD 3.05B 870M Jun/2025
ALKERMES USD 126.53M 105.32M Jun/2025
Amgen USD 3.6B 147M Jun/2025
AstraZeneca USD 4.96B 127M Jun/2025
Biogen USD 1.01B 456.5M Jun/2025
Bristol-Myers Squibb USD 3.27B 1.63B Jun/2025
Drreddys Laboratories INR 24.64B 1.33B Jun/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Gilead Sciences USD 3.4B 797M Jun/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
J&J USD 7.88B 1.76B Mar/2025
Medtronic USD 2.31B 400M Jul/2025
Merck USD 7.74B 625M Mar/2025
Novartis USD 6.17B 339M Jun/2025
Novo Nordisk 38.28B 4.34B Jun/2025
Perrigo USD 129.1M 1.9M Jun/2025
Pfizer USD 5.32B 889M Jun/2025
Prestige Brands USD 79.65M 28.5M Jun/2025
Regeneron Pharmaceuticals USD 1.66B 926.5M Jun/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 1.89B 971M Jun/2025
Sanofi EUR 1.89B 1.33B Jun/2025
United Therapeutics USD 436.8M 34.2M Jun/2025
Zoetis USD 1.08B 110M Jun/2025